Seminars in Hematology
Volume 43, Issue 2 , Pages 134-143 , April 2006

Approach to the Complications of Treatment for Acute Leukemia in the Elderly

  • Joel Gingerich

      Affiliations

    • Section of Haematology/Oncology, Department of Internal Medicine, the University of Manitoba, and the Department of Medical Oncology and Haematology, Cancer Care Manitoba, Winnipeg, Manitoba, Canada
    • ,
  • Eric J. Bow

      Affiliations

    • Sections of Infectious Diseases and Haematology/Oncology, Department of Internal Medicine, the University of Manitoba, and Department of Medical Oncology and Haematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada
    • E.J.B. is a Consultant and Investigator for Pfizer Global Pharmaceuticals, Astellas Pharma Canada, Inc, Merck Frosst Canada Ltd, AMGEN Canada Inc, Enzon Pharmaceuticals, Schering-Plough Pharmaceuticals, and Wyeth Pharmaceuticals.
    • Corresponding Author InformationAddress correspondence to E.J. Bow, MD, GD600, Health Sciences Centre, 820 Sherbrook St, Winnipeg, Manitoba, Canada R3A 1R9

References 

  1. Statistics Canada: Canadian statistics: Population and demography: Population characteristics . Population projections for 2110, 2006, 2011, 2016, 2021, and 2026, update . 2005; http://www.statcan.ca. accessed July 1
  2. Mclaughlin JR , Dryer D , Mao Y , Marrett L , Mills C , Morrison H , et al.   Canadian cancer statistics. Canadian Cancer Society/National Cancer Institute of Canada . 2005; http://www.cancer.ca. accessed July 1
  3. Heath CH . Epidemiology and hereditary aspects of acute leukemia . In:  Wiernik PH ,  Canellos GP ,  Dutcher JP ,  Kyle RA editor. Neoplastic Disease of the Blood . (ed 3).. New York, NY: Churchill-Livingston; 1996;p. 177
  4. Lichtman MA , Rowe JM . The relationship of patient age to the pathobiology of the clonal myeloid diseases . Semin Oncol . 2004;31:185–197
  5. Pagano L , Mele L , Trape G , Leone G . The treatment of acute lymphoblastic leukaemia in the elderly . Leuk Lymphoma . 2004;45:117–123
  6. Mayer RJ , Davis RB , Schiffer CA , Berg DT , Powell BL , Schulman P , et al.  Cancer and Leukemia Group B   Intensive postremission chemotherapy in adults with acute myeloid leukemia . N Engl J Med . 1994;331:896–903
  7. Rees JK , Gray RG , Swirsky D , Hayhoe FG . Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial . Lancet . 1986;2:1236–1241
  8. Appelbaum FR , Rowe JM , Radich J , Dick JE . Acute myeloid leukemia . Hematology (Am Soc Hematol Educ Program) . 2001;62–86
  9. Balducci L . The geriatric cancer patient (Equal benefit from equal treatment) . Cancer Control . 2001;8:1–25
  10. Zagonel V , Monfardini S , Tirelli U , Carbone A , Pinto A . Management of hematologic malignancies in the elderly (15-year experience at the Aviano Cancer Center, Italy) . Crit Rev Oncol Hematol . 2001;39:289–305
  11. Yancik R . Cancer burden in the aged (An epidemiologic and demographic overview) . Cancer . 1997;80:1273–1283
  12. Jemal A , Thomas A , Murray T , Thun M . Cancer statistics, 2002 . CA Cancer J Clin . 2002;52:23–47
  13. Godwin JE , Smith SE . Acute myeloid leukemia in the older patient . Crit Rev Oncol Hematol . 2003;48:S17–S26
  14. Grimwade D , Walker H , Harrison G , Oliver F , Chatters S , Harrison CJ , et al.   The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML) (Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial) . Blood . 2001;98:1312–1320
  15. Leith CP , Kopecky KJ , Godwin J , McConnell T , Slovak ML , Chen IM , et al.  A Southwest Oncology Group study   Acute myeloid leukemia in the elderly (Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy) . Blood . 1997;89:3323–3329
  16. Wahlin A , Markevarn B , Golovleva I , Nilsson M . Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation . Eur J Haematol . 2002;68:54–63
  17. Wahlin A , Markevarn B , Golovleva I , Nilsson M . Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia . Br J Haematol . 2001;115:25–33
  18. Robak T . Acute lymphoblastic leukaemia in elderly patients (Biological characteristics and therapeutic approaches) . Drugs Aging . 2004;21:779–791
  19. Trimble EL , Carter CL , Cain D , Freidlin B , Ungerleider RS , Friedman MA . Representation of older patients in cancer treatment trials . Cancer . 1994;74:2208–2214
  20. Hutchins LF , Unger JM , Crowley JJ , Coltman CA , Albain KS . Underrepresentation of patients 65 years of age or older in cancer-treatment trials . N Engl J Med . 1999;341:2061–2067
  21. Taylor PR , Reid MM , Stark AN , Bown N , Hamilton PJ , Proctor SJ  Northern Region Haematology Group . De novo acute myeloid leukaemia in patients over 55-years-old (A population-based study of incidence, treatment and outcome) . Leukemia . 1995;9:231–237
  22. Rathnasabapathy R , Lancet JE . Management of acute myelogenous leukemia in the elderly . Cancer Control . 2003;10:469–477
  23. Begg CB , Carbone PP  The experience of the Eastern Cooperative Oncology Group . Clinical trials and drug toxicity in the elderly . Cancer . 1983;52:1986–1992
  24. Dale DC . Poor prognosis in elderly patients with cancer (The role of bias and undertreatment) . J Support Oncol . 2003;1:11–17
  25. Basso U , Monfardini S . Multidimensional geriatric evaluation in elderly cancer patients (A practical approach) . Eur J Cancer Care (Engl) . 2004;13:424–433
  26. Satariano WA , Silliman RA . Comorbidity (Implications for research and practice in geriatric oncology) . Crit Rev Oncol Hematol . 2003;48:239–248
  27. Yancik R , Wesley MN , Ries LA , Havlik RJ , Edwards BK , Yates JW . Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older . JAMA . 2001;285:885–892
  28. Mandelblatt JS , Edge SB , Meropol NJ , Senie R , Tsangaris T , Grey L , et al.   Predictors of long-term outcomes in older breast cancer survivors (Perceptions versus patterns of care) . J Clin Oncol . 2003;21:855–863
  29. Charlson ME , Pompei P , Ales KL , MacKenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies (Development and validation) . J Chronic Dis . 1987;40:373–383
  30. Miller MD , Paradis CF , Houck PR , Mazumdar S , Stack JA , Rifai AH , et al.   Rating chronic medical illness burden in geropsychiatric practice and research (Application of the Cumulative Illness Rating Scale) . Psychiatry Res . 1992;41:237–248
  31. Extermann M , Overcash J , Lyman GH , Parr J , Balducci L . Comorbidity and functional status are independent in older cancer patients . J Clin Oncol . 1998;16:1582–1587
  32. De Cicco M , Bortolussi R , Fantin D , Matovic M , Fracasso A , Fabiani F , et al.   Supportive therapy of elderly cancer patients . Crit Rev Oncol Hematol . 2002;42:189–211
  33. Dewys WD , Begg C , Lavin PT , Band PR , Bennett JM , Bertino JR , et al.  Eastern Cooperative Oncology Group   Prognostic effect of weight loss prior to chemotherapy in cancer patients . Am J Med . 1980;69:491–497
  34. Harris CL , Fraser C . Malnutrition in the institutionalized elderly (The effects on wound healing) . Ostomy Wound Manage . 2004;50:54–63
  35. Gonzalez-Gross M , Marcos A , Pietrzik K . Nutrition and cognitive impairment in the elderly . Br J Nutr . 2001;86:313–321
  36. Lichtman SM . Guidelines for the treatment of elderly cancer patients . Cancer Control . 2003;10:445–453
  37. Balducci L . Anemia, cancer, and aging . Cancer Control . 2003;10:478–486
  38. Christman K , Muss HB , Case LD , Stanley V  The Piedmont Oncology Association experience . Chemotherapy of metastatic breast cancer in the elderly . JAMA . 1992;268:57–62
  39. Ershler WB . Biological interactions of aging and anemia (A focus on cytokines) . J Am Geriatr Soc . 2003;51:S18–S21
  40. Hamerman D , Berman JW , Albers GW , Brown DL , Silver D . Emerging evidence for inflammation in conditions frequently affecting older adults (Report of a symposium) . J Am Geriatr Soc . 1999;47:1016–1025
  41. Craft S , Cholerton B , Reger M . Aging and cognition. What is normal? . In:  Hazzard WR ,  Blass JP ,  Halter JB ,  Ouslander JG ,  Tinetti ME editor. Principles of Geriatric Medicine and Gerontology . (ed 5).. York, PA: McGraw-Hill; 2003;p. 1355–1372
  42. Noale M , Maggi S , Minicuci N , Marzari C , Destro C , Farchi G , et al.  The Italian Longitudinal Study on Aging   Dementia and disability (Impact on mortality) . Dement Geriatr Cogn Disord . 2003;16:7–14
  43. Balducci L , Yates J . General guidelines for the management of older patients with cancer . Oncology (Williston Park) . 2000;14:221–227
  44. Folstein MF , Folstein SE , McHugh PR . “Mini-Mental State.” A practical method for grading the cognitive state of patients for the clinician . J Psychiatr Res . 1975;12:189–198
  45. Hanlon JT , Lindblad CI , Hajjar ER , McCarthy TC . Update on drug-related problems in the elderly . Am J Geriatr Pharmacother . 2003;1:38–43
  46. Baker SD , Grochow LB . Pharmacology of cancer chemotherapy in the older person . Clin Geriatr Med . 1997;13:169–183
  47. Yuen GJ . Altered pharmacokinetics in the elderly . Clin Geriatr Med . 1990;6:257–267
  48. Balducci L , Extermann M . Management of cancer in the older person (A practical approach) . Oncologist . 2000;5:224–237
  49. Wiggins J . Changes in renal function . In:  Hazzard WR ,  Blass JP ,  Halter JB ,  Ouslander JG ,  Tinetti ME editor. Principles of Geriatric Medicine and Gerontology . (ed 5).. York, PA: McGraw-Hill; 2003;p. 543–581
  50. Cockcroft DW , Gault MH . Prediction of creatinine clearance from serum creatinine . Nephron . 1976;16:31–41
  51. Jelliffe RW . Estimation of creatinine clearance when urine cannot be collected . Lancet . 1971;1:975–976
  52. Marx GM , Blake GM , Galani E , Steer CB , Harper SE , Adamson KL , et al.   Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients . Ann Oncol . 2004;15:291–295
  53. Bow EJ , Sutherland JA , Kilpatrick MG , Williams GJ , Clinch JJ , Shore TB , et al.   Therapy of untreated acute myeloid leukemia in the elderly (remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide) . J Clin Oncol . 1996;14:1345–1352
  54. Duncan M , Grant G . Oral and intestinal mucositis—Causes and possible treatments . Aliment Pharmacol Ther . 2003;18:853–874
  55. Sonis ST , Elting LS , Keefe D , Peterson DE , Schubert M , Hauer-Jensen M , et al.   Perspectives on cancer therapy-induced mucosal injury (Pathogenesis, measurement, epidemiology, and consequences for patients) . Cancer . 2004;100:1995–2025
  56. Sonis ST . Pathobiology of mucositis . Semin Oncol Nurs . 2004;20:11–15
  57. Balducci L , Corcoran MB . Antineoplastic chemotherapy of the older cancer patient . Hematol Oncol Clin North Am . 2000;14:193–212
  58. Nebert DW , Russell DW . Clinical importance of the cytochromes P450 . Lancet . 2002;360:1155–1162
  59. Colburn DE , Giles FJ , Oladovich D , Smith JA . In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin . Hematology . 2004;9:217–221
  60. Marr KA , Leisenring W , Crippa F , Slattery JT , Corey L , Boeckh M , et al.   Cyclophosphamide metabolism is affected by azole antifungals . Blood . 2004;103:1557–1559
  61. Rollason V , Vogt N . Reduction of polypharmacy in the elderly (A systematic review of the role of the pharmacist) . Drugs Aging . 2003;20:817–832
  62. Extermann M , Chen H , Cantor AB , Corcoran MB , Meyer J , Grendys E , et al.   Predictors of tolerance to chemotherapy in older cancer patients (A prospective pilot study) . Eur J Cancer . 2002;38:1466–1473
  63. Shan K , Lincoff AM , Young JB . Anthracycline-induced cardiotoxicity . Ann Intern Med . 1996;125:47–58
  64. Kansal V , Omura GA , Soong SJ . Prognosis in adult acute myelogenous leukemia related to performance status and other factors . Cancer . 1976;38:329–334
  65. Katz S , Ford AB , Moskowitz RW , Jackson BA , Jaffe MW . Studies of illness in the aged. The index of ADL (A standardized measure of biological and psychological function) . JAMA . 1963;185:914–919
  66. Lawton MP , Brody EM . Assessment of older people (Self-maintaining and instrumental activities of daily living) . Gerontologist . 1969;9:179–186
  67. Reuben DB , Rubenstein LV , Hirsch SH , Hays RD . Value of functional status as a predictor of mortality (Results of a prospective study) . Am J Med . 1992;93:663–669
  68. Cella DF , Tulsky DS , Gray G , Sarafian B , Linn E , Bonomi A , et al.   The Functional Assessment of Cancer Therapy scale (Development and validation of the general measure) . J Clin Oncol . 1993;11:570–579
  69. Rockwood K , Song X , MacKnight C , Bergman H , Hogan DB , McDowell I , et al.   A global clinical measure of fitness and frailty in elderly people . CMAJ . 2005;173:489–495
  70. Stuck AE , Siu AL , Wieland GD , Adams J , Rubenstein LZ . Comprehensive geriatric assessment (a meta-analysis of controlled trials) . Lancet . 1993;342:1032–1036
  71. Balducci L . New paradigms for treating elderly patients with cancer (The comprehensive geriatric assessment and guidelines for supportive care) . J Support Oncol . 2003;1:30–37
  72. Alcalai R , Ben-Yehuda D , Ronen I , Paltiel O . Ethnicity and prognosis in acute myeloid leukemia . Am J Hematol . 2003;72:127–134
  73. Lachs MS , Feinstein AR , Cooney LM , Drickamer MA , Marottoli RA , Pannill FC , et al.   A simple procedure for general screening for functional disability in elderly patients . Ann Intern Med . 1990;112:699–706
  74. Extermann M , Meyer J , McGinnis M , Crocker TT , Corcoran MB , Yoder J , et al.   A comprehensive geriatric intervention detects multiple problems in older breast cancer patients . Crit Rev Oncol Hematol . 2004;49:69–75
  75. McCorkle R , Strumpf NE , Nuamah IF , Adler DC , Cooley ME , Jepson C , et al.   A specialized home care intervention improves survival among older post-surgical cancer patients . J Am Geriatr Soc . 2000;48:1707–1713
  76. Podsiadlo D , Richardson S . The timed “Up & Go” (A test of basic functional mobility for frail elderly persons) . J Am Geriatr Soc . 1991;39:142–148
  77. Walter LC , Brand RJ , Counsell SR , Palmer RM , Landefeld CS , Fortinsky RH , et al.   Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization . JAMA . 2001;285:2987–2994
  78. Walter LC , Covinsky KE . Cancer screening in elderly patients (A framework for individualized decision making) . JAMA . 2001;285:2750–2756
  79. Rowe JM . Treatment of acute myeloid leukemia with cytokines (Effect on duration of neutropenia and response to infection) . Clin Infect Dis . 1998;26:1290–1294
  80. Rowe JM , Andersen JW , Mazza JJ , Bennett JM , Paietta E , Hayes FA , et al.   A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia (A study of the Eastern Cooperative Oncology Group (E1490)) . Blood . 1995;86:457–462
  81. Buchner T , Hiddemann W , Koenigsmann M , Zuhlsdorf M , Wormann B , Boeckmann A , et al.   Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse . Blood . 1991;78:1190–1197
  82. Dombret H , Chastang C , Fenaux P , Reiffers J , Bordessoule D , Bouabdallah R , et al.  AML Cooperative Study Group   A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia . N Engl J Med . 1995;332:1678–1683
  83. Link H , Wandt H , Schonrock-Nabulsi R , Ehninger G , Franke A , Gackle R , et al.   G-CSF (lenograstim) after chemotherapy for acute myeloid leukemia (A placebo controlled trial) . Blood . 1996;88:2654a; (suppl 1, abstr)
  84. Goldstone AH , Burnett AK , Wheatley K , Smith AG , Hutchinson RM , Clark RE . Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients (The results of the United Kingdom Medical Research Council AML11 trial) . Blood . 2001;98:1302–1311
  85. Amadori S , Suciu S , Jehn U , Stasi R , Thomas X , Marie JP , et al.   Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia (Final results of AML-13, a randomized phase-3 study) . Blood . 2005;106:27–34
  86. Ohno R , Tomonaga M , Koboyashi T , Kanamaru A , Shirakawa S , Masaoka T , et al.   Effect of granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia . N Engl J Med . 1990;323:871–877
  87. Ohno R , Naoe T , Kanamaru A , Yoshida M , Hiraoka A , Kobayashi T , et al.   A double-blind controlled study of granulocyte colony-stimulating factor stared two days before induction chemotherapy in refractory acute myeloid leukemia . Blood . 1994;83:2086–2092
  88. Estey E , Thall P , Andreef M , Beran M , Kantarjian H , O’Brien S , et al.   Use of granulocyte colony-stimulating factor before, during, and after fludarbine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes (Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor) . J Clin Oncol . 1994;12:671–678
  89. Godwin JE , Kopecky KJ , Head DR , Willman CL , Leith CP , Hynes HE , et al.   A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia (A Southwest Oncology Group study (9031)) . Blood . 1998;91:3607–3615
  90. Heil G , Hoelzer D , Sanz MA , Lechner K , Liu Yin JA , Papa G , et al.  The International Acute Myeloid Leukemia Study Group   A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia . Blood . 1997;90:4710–4718
  91. Stone RM , Berg DT , George SL , Dodge RK , Paciucci PA , Schulman P , et al.  Cancer and Leukemia Group B   Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia . N Engl J Med . 1995;332:1671–1677
  92. Lowenberg B , Suciu S , Archimbaud E , Ossenkoppele G , Verhoef GE , Vellenga E , et al.   Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group) . Blood . 1997;90:2952–2961
  93. Zittoun R , Suciu S , Mandelli F , De Witte T , Thaler J , Stryckmans P , et al.   Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia (A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group) . J Clin Oncol . 1996;14:2150–2159
  94. Witz F , Sadoun A , Perrin MC , Berthou C , Briere J , Cahn JY , et al.  Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM)   A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients . Blood . 1998;91:2722–2730
  95. Schiffer CA . Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia . Blood . 1996;88:3675–3685
  96. Geller RB . Use of cytokines in the treatment of acute myelocytic leukemia (A critical review) . J Clin Oncol . 1996;14:1371–1382
  97. Lofgren C , Paul C , Astrom M , Hast R , Hedenius M , Lerner R , et al.   Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia (A Swedish multicentre randomized trial) . Br J Haematol . 2004;124:474–480
  98. Amadori S , Suciu S , Willemze R , Mandelli F , Selleslag D , Stauder R , et al.   Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia (A phase II study (AML-15) of the EORTC and GIMEMA leukemia groups) . Haematologica . 2004;89:950–956
  99. Ozer H , Armitage JO , Bennett CL , Crawford J , Demetri GD , Pizzo PA , et al.   2000 update of recommendations for the use of hematopoietic colony-stimulating factors (Evidence-based, clinical practice guidelines) . J Clin Oncol . 2000;18:3558–3585
  100. Bennett CL , Stinson TJ , Tallman MS , Stadtmauer EA , Marsh RW , Friedenberg W , et al.  Eastern Cooperative Oncology Group (E1490)   Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia . Ann Oncol . 1999;10:177–182
  101. Woronoff-Lemsi MC , Witz F , Arveux P , Cahn JY , Harousseau JL . Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients (protocol of GOELAM Sa3) . Therapie . 2001;56:131–133
  102. Bennett CL , Hynes D , Godwin J , Stinson TJ , Golub RM , Appelbaum FR . Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML) (Estimates from a Southwest Oncology Group clinical trial) . Cancer Invest . 2001;19:603–610
  103. Rubenstein EB , Peterson DE , Schubert M , Keefe D , McGuire D , Epstein J , et al.   Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis . Cancer . 2004;100:2026–2046
  104. Benson AB , Ajani JA , Catalano RB , Engelking C , Kornblau SM , Martenson JA , et al.   Recommended guidelines for the treatment of cancer treatment-induced diarrhea . J Clin Oncol . 2004;22:2918–2926
  105. Sonis ST , Oster G , Fuchs H , Bellm L , Bradford WZ , Edelsberg J , et al.   Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation . J Clin Oncol . 2001;19:2201–2205
  106. Bow EJ , Loewen R , Cheang MS , Shore TB , Rubinger M , Schacter B . Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults . J Clin Oncol . 1997;15:2254–2261
  107. Blijlevens NM , Donnelly JP , De Pauw BE . Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant . Bone Marrow Transplant . 2005;35:707–711
  108. Blijlevens NM , van’t Land B , Donnelly JP , M’Rabet L , De Pauw BE . Measuring mucosal damage induced by cytotoxic therapy . Support Care Cancer . 2004;12:227–233
  109. Spielberger R , Stiff P , Bensinger W , Gentile T , Weisdorf D , Kewalramani T , et al.   Palifermin for oral mucositis after intensive therapy for hematologic cancers . N Engl J Med . 2004;351:2590–2598
  110. Gorschluter M , Mey U , Strehl J , Ziske C , Schepke M , Schmidt-Wolf IG , et al.   Neutropenic enterocolitis in adults (Systematic analysis of evidence quality) . Eur J Haematol . 2005;75:1–13
  111. Rao A , Cohen HJ . Symptom management in the elderly cancer patient (Fatigue, pain, and depression) . J Natl Cancer Inst Monogr . 2004;32:150–157
  112. Ferrell BA , Chodosh J . Pain management . In:  Hazzard WR ,  Blass JP ,  Halter JB ,  Ouslander JG ,  Tinetti ME editor. Principles of Geriatric Medicine and Gerontology . (ed 5).. York, PA: McGraw-Hill; 2003;p. 303–321
  113. Agostini JV , Inouye SK . Delirium . In:  Hazzard WR ,  Blass JP ,  Halter JB ,  Ouslander JG ,  Tinetti ME editor. Principles of Geriatric Medicine and Gerontology . (ed 5).. York, PA: McGraw-Hill; 2003;p. 1503–1516
  114. Bow EJ . Infectious complications in patients receiving cytotoxic therapy for acute leukemia (History, background and approaches to management) . In:  Wingard JR ,  Bowden RA editor. Management of Infection in Oncology Patients . London, UK: Martin Dunitz; 2003;p. 71–104
  115. Garcia-Suarez J , Krsnik I , Reyes E , De MD , Hernanz N , Barr-Ali M , et al.   Elderly haematological patients with chemotherapy-induced febrile neutropenia have similar rates of infection and outcome to younger adults (A prospective study of risk-adapted therapy) . Br J Haematol . 2003;120:209–216
  116. Masaoka T . Economic issues (Toward a cost-effective approach to the management of febrile neutropenia in Japan) . Clin Infect Dis . 2004;39(suppl 1):S68–S69
  117. Yoshida M , Ohno R . Antimicrobial prophylaxis in febrile neutropenia . Clin Infect Dis . 2004;39(suppl 1):S65–S67
  118. Cruciani M , Rampazzo R , Malena M , Lazzarini L , Todeschini G , Messori A , et al.   Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients (A meta-analysis) . Clin Infect Dis . 1996;23:795–805
  119. Cruciani M , Malena M , Bosco O , Nardi S , Serpelloni G , Mengoli C . Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients . J Clin Oncol . 2003;21:4127–4137
  120. Rotstein C , Mandell L , Goldberg N . Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients (A meta-analysis) . Curr Oncol . 1997;4(suppl 2):S2–S7
  121. Engels EA , Lau J , Barza M . Efficacy of quinolone prophylaxis in neutropenic cancer patients (A meta-analysis) . J Clin Oncol . 1998;16:1179–1187
  122. Gafter-Gvili A , Fraser A , Paul M , Leibovici L . Meta-analysis (Antibiotic prophylaxis reduces mortality in neutropenic patients) . Ann Intern Med . 2005;142:979–995
  123. Bow EJ . Point (Fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined populations, but must be used wisely) . J Natl Compr Cancer Network . 2004;2:433–444
  124. Kleinberg M . Counterpoint (Routine anti-bacterial prophylaxis is not indicated in neutropenic patients with hematological maligancies) . J Natl Compr Cancer Network . 2004;2:445–451
  125. Pena C , Albareda JM , Pallares R , Pujol M , Tubau F , Ariza J . Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections . Antimicrob Agents Chemother . 1995;39:520–524
  126. Perea S , Hidalgo M , Arcediano A , Ramos MJ , Gomez C , Hornedo J , et al.   Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis . J Antimicrob Chemother . 1999;44:117–120
  127. Gomez L , Garau J , Estrada C , Marquez M , Dalmau D , Xercavins M , et al.   Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli . Cancer . 2003;97:419–424
  128. Bochud P-Y , Eggiman P , Calandra T , Van Melle G , Saghafi L , Francioli P . Bacteremia due to viridans streptococcus in neutropenic patients with cancer (Clinical spectrum and risk factors) . Clin Infect Dis . 1994;18:25–31
  129. Viscoli C , Bruzzi P , Castagnola E , Boni L , Calandra T , Gaya H , et al.   Factors associated with bacteremia in febrile, granulocytopenic cancer patients . Eur J Cancer . 1994;30A:430–437
  130. Elting LS , Rubenstein EB , Rolston KV , Bodey GP . Outcomes of bacteremia in patients with cancer and neutropenia (Observations from two decades of epidemiological and clinical trials) . Clin Infect Dis . 1997;25:247–259
  131. Elting LS , Bodey GP , Keefe BH . Septicemia and shock syndrome due to viridans streptococci (A case-control study of predisposing factors) . Clin Infect Dis . 1992;14:1201–1207
  132. Gotzsche PC , Johansen HK . Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia . BMJ . 1997;314:1238–1244
  133. Kanda Y , Yamamoto R , Chizuka A , Hamaki T , Suguro M , Arai C , et al.   Prophylactic action of oral fluconazole against infection in neutropenic patients—A meta-analysis of 16 randomized, controlled trials . Cancer . 2000;89:1611–1625
  134. Bow EJ , Laverdiere M , Lussier N , Rotstein C , Cheang MS , Ioannou S . Antifungal prophylaxis for severely neutropenic chemotherapy recipients (A meta analysis of randomized-controlled clinical trials) . Cancer . 2002;94:3230–3246
  135. Glasmacher A , Prentice A , Gorschluter M , Engelhart S , Hahn C , Djulbegovic B , et al.   Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies (Evidence from a meta-analysis of 3,597 patients) . J Clin Oncol . 2003;21:4615–4626
  136. Cornely OA , Ullmann AJ , Karthaus M . Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies . Blood . 2003;101:3365–3372
  137. Marr KA , Crippa F , Leisenring W , Hoyle M , Boeckh M , Balajee SA , et al.   Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants . Blood . 2004;103:1527–1533
  138. Rotstein C , Bow EJ , Laverdiere M , Ioannou S , Carr D , Moghaddam N  The Canadian Fluconazole Prophylaxis Study Group . Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients (Benefit based on purpose and intensity of cytotoxic therapy) . Clin Infect Dis . 1999;28:331–340
  139. Hughes WT , Armstrong D , Bodey GP , Bow EJ , Brown AE , Calandra T , et al.   2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer . Clin Infect Dis . 2002;34:730–751
  140. Link H , Bohme A , Cornely OA , Hoffken K , Kellner O , Kern WV , et al.   Antimicrobial therapy of unexplained fever in neutropenic patients—Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society) . Ann Hematol . 2003;82(suppl 2):S105–S117
  141. Freifeld AG , Baden LR , Brown AE , Elting L , Gelfand M , Greene JN , et al.   Fever and neutropenia . J Natl Comp Cancer Network . 2004;2:390–432
  142. Masaoka T . Febrile neutropenia—Guideline in Japan . Gan To Kagaku Ryoho . 2000;27:161–165
  143. Crivellari D , Lombardi D , Spazzapan S , Veronesi A , Toffoli G . New oral drugs in older patients (A review of idarubicin in elderly patients) . Crit Rev Oncol Hematol . 2004;49:153–163
  144. Masaoka T . Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan (Executive summary) . Clin Infect Dis . 2004;39(suppl 1):S49–S52
  145. Garcia-Rodriguez JA , Gobernado M , Gomis M , Mensa J , Picazo J , Prieto J , et al.   Clinical guide for the evaluation and treatment of patients with neutropenia and fever . Rev Esp Quimioter . 2001;14:75–83
  146. Klastersky J , Paesmans M , Rubenstein EB , Boyer M , Elting L , Feld R , et al.   The Multinational Association for Supportive Care in Cancer risk index (A multinational scoring system for identifying low-risk febrile neutropenic cancer patients) . J Clin Oncol . 2000;18:3038–3051
  147. Paul M , Soares-Weiser K , Leibovici L . Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia (Systematic review and meta-analysis) . BMJ . 2003;326:1111–1120
  148. Furno P , Bucaneve G , Del Favero A . Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients (a meta-analysis) . Lancet Infect Dis . 2002;2:231–242
  149. Viscoli C . Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG) . Eur J Cancer . 2002;38(suppl 4):S82–S87
  150. Wade JC , Glasmacher A . Vancomycin does not benefit persistently febrile neutropenic people with cancer . Cancer Treat Rev . 2004;30:119–126
  151. Bow EJ , Noskin GA , Schwarer AP , Laverdiere M , Vesole DH . Efficacy of piperacillin/tazobactam as initial empiric therapy for febrile neutropenia in patients with hematological malignancy . Blood . 2003;102:281a; (abstr 1000)
  152. Bow EJ , Laverdière M , Rotstein C . In: A systematic review of the efficacy of azoles and lipid-based formulations of amphotericin B as empirical anti-fungal therapy in persistently febrile neutropenic patients despite broad-spectrum anti-bacterial therapy . Toronto, Canada: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000;p. 364; September 17-20, (abstr 702)
  153. Walsh TJ , Finberg RW , Arndt C , Hiemenz J , Schwartz C , Bodensteiner D , et al.  National Institute of Allergy and Infectious Diseases Mycoses Study Group   Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia . N Engl J Med . 1999;340:764–771
  154. Barrett JP , Vardulaki KA , Conlon C , Cooke J , Daza-Ramirez P , Evans EG , et al.   A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations . Clin Ther . 2003;25:1295–1320
  155. Boogaerts M , Winston DJ , Bow EJ , Garber G , Reboli AC , Schwarer AP , et al.   Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial . Ann Intern Med . 2001;135:412–422
  156. Walsh TJ , Pappas P , Winston DJ , Lazarus HM , Petersen F , Raffalli J , et al.   Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever . N Engl J Med . 2002;346:225–234
  157. Walsh TJ , Teppler H , Donowitz GR , Maertens JA , Baden LR , Dmoszynska A , et al.   Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia . N Engl J Med . 2004;351:1391–1402
  158. Ascioglu S , Rex JH , de Pauw B , Bennett JE , Bille J , Crokaert F , et al.   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants (An international consensus) . Clin Infect Dis . 2002;34:7–14
  159. Martino R , Subira M , Rovira M , Solano C , Vazquez L , Sanz GF , et al.   Invasive fungal infections after allogeneic peripheral blood stem cell transplantation (Incidence and risk factors in 395 patients) . Br J Haematol . 2002;116:475–482
  160. Mermel LA , Farr BM , Sherertz RJ , Raad II , O’Grady N , Harris JS , et al.   Guidelines for the management of intravascular catheter-related infections . Clin Infect Dis . 2001;32:1249–1272
  161. Azoulay E , Darmon M , Delclaux C , Fieux F , Bornstain C , Moreau D , et al.   Deterioration of previous acute lung injury during neutropenia recovery . Crit Care Med . 2002;30:781–786
  162. Barnes SG , Sattler FR , Ballard JO . Perirectal infections in acute leukemia—Improved survival after incision and debridement . Ann Intern Med . 1984;100:515–518
  163. Maschmeyer G , Link H , Hiddemann W , Meyer P , Helmerking M , Eisenmann E , et al.   Pulmonary infiltrates in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study . Cancer . 1994;73:2296–2304
  164. Gomez L , Martino R , Rolston KV . Neutropenic enterocolitis (Spectrum of the disease and comparison of definite and possible cases) . Clin Infect Dis . 1998;27:695–699

PII: S0037-1963(06)00018-7

doi: 10.1053/j.seminhematol.2006.01.001

Seminars in Hematology
Volume 43, Issue 2 , Pages 134-143 , April 2006

Article Tools